Prashant Jagannath Chaudhari, Aditya Ramchandra Nemade and Atul Arun Shirkhedkar
RSC Adv., 2024,14, 33384-33417
From themed collection:
2024 Reviews in RSC Advances
Abstract
Essential structural motifs for design of Lead against VEGFR-2.
Aalaa F. El-Mokadem, Mohammed K. Abd El-Gaber, Pak Hei Chung, Siang-Boon Koh, Hoda Y. Hassan and Adel F. Youssef
RSC Med. Chem., 2025,16, 3645-3670
Abstract
A series of novel 2-oxoindolin-3-ylidene thiazole derivatives were designed and synthesized, inspired by the pharmacophoric features of the VEGFR-2 inhibitor sunitinib.
Randa Atef Ibrahim Abdelaziz, Heba Abdelrasheed Allam, Ahmed Mahmoud El Kerdawy, Mahmoud Taha Abo-Elfadl, Safinaz El-Sayed Abbas and Iman Ahmed Youssef Ghannam
RSC Med. Chem., 2025,16, 6299-6318
Abstract
A chalcone-based thiopyrimidine (4c) has displayed a potent anticancer activity via VEGFR-2 and BRAF inhibition.
Hussam Elddin Nabeih Khasawneh, Hesham M. Hassan, Amal Ali Alharbi, Wesam Taher Almagharbeh, Raed Fanoukh Aboqader Al-Aouadi, Kirandeep Kaur, Ramya Maranan, Hadeer M. Farhan, Hamada Hashem, Mariam M. Hassan, Stefan Bräse and Ahmed Al-Emam
RSC Adv., 2025,15, 40998-41047
Abstract
Epidermal growth factor receptor (EGFR) is a validated oncogenic driver in numerous solid tumors, and resistance to first- and second-generation tyrosine kinase inhibitors continues to limit clinical outcomes.
Atukuri Dorababu
RSC Med. Chem., 2024,15, 416-432
Abstract
The review describes anti-VEGFR-2 activity of heterocycles including quinazoles, pyrimidines, isatin and azoles considering SAR for a given set of derivatives. Compounds with potent activity were emphasized with description of structural features.